Public Research Snapshot
Vyome Holdings Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates.
HIND Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway
Vyome Holdings Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z
TickerHIND
Market Cap16.3M
Cash RunwayRunway 6-12 months
Next Catalystn/a
Pipeline
| Asset | Indication | Modality | Stage | Public Note |
|---|---|---|---|---|
| No public pipeline rows are loaded yet. | ||||
Catalyst Preview
No public catalyst rows matched this view yet.
Cash Runway Preview
Estimated cash runway: Runway 6-12 months.
This is an automated estimate and may differ from company guidance.
Recent SEC Filings
- No public filing rows are loaded yet.
Clinical Trial Activity
| NCT ID | Phase | Status | Enrollment | Primary Completion |
|---|---|---|---|---|
| No public trial rows are loaded yet. | ||||
Scientific Context
- literature_publication | β-lactam resistant phenotypes reported by VITEK®2 advanced expert system(TM) (AES) compared to whole genome sequencing in Enterobacterales from North and Latin America.
- literature_publication | Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
- literature_publication | A potent antibiotic-loaded bone-cement implant against staphylococcal bone infections.
- literature_publication | β-lactam resistant phenotypes reported by VITEK®2 advanced expert system(TM) (AES) compared to whole genome sequencing in Enterobacterales from North and Latin America.
- literature_publication | Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
Want the full HIND research brief?
Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.
Get the weekly biotech catalyst watchlistThis page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.